Drugs / Anti-HER2/HER3 Dendritic Cell Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04348747 | Dec 2022 → Jun 2027 expected | metastatic malignant neoplasm in the brain, triple-negative breast carcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-HER2/HER3 Dendritic Cell Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04348747 ↗ |
| Action | Deplete | “recognize and destroy the cancer cells” NCT04348747 ↗ |
| Modality | Vaccine | “dendritic cell vaccines” NCT04348747 ↗ |
| Route | Other | “intradermally (ID)” NCT04348747 ↗ |